SC-CAR4BRAIN

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameSC-CAR4BRAIN
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-CD276Anti-HER2 +[4] 
TargetsEpidermal growth factor receptor erbB1CD276 antigenReceptor protein-tyrosine kinase erbB-2 +[4] 
Therapy Area/IndicationsDiffuse midline gliomaCentral Nervous System NeoplasmsDiffuse Intrinsic Pontine Glioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesSeattle Children'S Hospital
Inactive CompaniesN/A
Active IndicationsDiffuse midline gliomaCentral Nervous System NeoplasmsDiffuse Intrinsic Pontine Glioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A